Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2010

01-06-2010 | Original Article

Elevated Serum Matrix Metalloproteinase-3 and -7 in H. pylori-Related Gastric Cancer Can Be Biomarkers Correlating with a Poor Survival

Authors: Yi-Chun Yeh, Bor-Shyang Sheu, Hsiu-Chi Cheng, Yen-Lin Wang, Hsiao-Bai Yang, Jiunn-Jong Wu

Published in: Digestive Diseases and Sciences | Issue 6/2010

Login to get access

Abstract

Background

Helicobacter pylori (H. pylori) infection up-regulates the expression of matrix metalloproteinases (MMPs), which may be involved in chronic inflammation, ulceration, and even cancer development. This study aimed to test if serum levels of MMP-3, -7, and -9 are correlated with different clinical outcomes in H. pylori-infected subjects and if these are predictive of progression to H. pylori-related gastric cancer.

Method

Two hundred one patients, 28 with H. pylori-negative gastritis and 173 with different H. pylori-positive gastrointestinal diseases (46 gastritis, 43 duodenal ulcers, 29 gastric ulcers, and 55 gastric cancers) were assessed for serum MMP-3, -7, and -9 titers by enzyme-linked immunosorbent assay and validated to their correlations with the different clinical features and survival of patients with H. pylori-positive gastric cancer.

Results

Among the H. pylori-infected subjects, gastric cancer patients had higher serum levels of MMP-3 and MMP-7 than those with duodenal ulcer and gastritis (P < 0.05). For gastric cancer patients, concomitant elevated MMP-3 (>14 ng/ml) and MMP-7 (>4.5 ng/ml) independently correlated with lymph node invasion (P < 0.05) and could be predictive to have shorter 2- or 5-year survivals (log rank test, P = 0.006).

Conclusion

Concomitant elevations of MMP-3 and MMP-7 serum levels in the H. pylori-infected gastric cancer patients could serve as potential biomarkers to correlate with poor survival.
Literature
1.
Steer HW. Surface morphology of the gastroduodenal mucosa in duodenal ulceration. Gut. 1984;25:1203–1210.CrossRefPubMed
2.
Warren JR MB. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–1275.
3.
Labigne A, de Reuse H. Determinants of Helicobacter pylori pathogenicity. Infect Agents Dis. 1996;5:191–202.PubMed
4.
Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev. 1997;10:720–741.PubMed
5.
Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med. 1994;120:977–981.PubMed
6.
7.
Wroblewski LE, Noble PJ, Pagliocca A, et al. Stimulation of MMP-7 (matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration. J Cell Sci. 2003;116:3017–3026.CrossRefPubMed
8.
Mori N, Sato H, Hayashibara T, et al. Helicobacter pylori induces matrix metalloproteinase-9 through activation of nuclear factor kappaB. Gastroenterology. 2003;124:983–992.CrossRefPubMed
9.
Crawford HC, Krishna US, Israel DA, et al. Helicobacter pylori strain-selective induction of matrix metalloproteinase-7 in vitro and within gastric mucosa. Gastroenterology. 2003;125:1125–1136.CrossRefPubMed
10.
Bebb JR, Letley DP, Thomas RJ, et al. Helicobacter pylori upregulates matrilysin (MMP-7) in epithelial cells in vivo and in vitro in a Cag dependent manner. Gut. 2003;52:1408–1413.CrossRefPubMed
11.
12.
Lee KH, Shin SJ, Kim KO, et al. Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep. 2006;16:823–830.PubMed
13.
Ohashi K, Nemoto T, Nakamura K, et al. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer. 2000;88:2201–2209.CrossRefPubMed
14.
Mori M, Barnard GF, Mimori K, et al. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer. 1995;75:1516–1519.CrossRefPubMed
15.
Hoikkala S, Paakko P, Soini Y, et al. Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2–complex or TIMP-1 in stage I-III lung carcinoma. Cancer Lett. 2006;236:125–132.CrossRefPubMed
16.
Zucker S, Lysik RM, Zarrabi MH, et al. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993;53:140–146.PubMed
17.
Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer. 2005;116:422–427.CrossRefPubMed
18.
Wu CY, Wu MS, Chiang EP, et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res. 2007;13:2054–2060.CrossRefPubMed
19.
Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 1999;24:73–76.CrossRefPubMed
20.
Tlsty TD. Cell-adhesion-dependent influences on genomic instability and arcinogenesis. Curr Opin Cell Biol. 1998;10:647–653.CrossRefPubMed
21.
Tas F, Duranyildiz D, Oguz H, et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol. 2005;22:39–44.CrossRefPubMed
22.
Gohji K, Fujimoto N, Komiyama T, et al. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer. 1996;78:2379–2387.CrossRefPubMed
23.
Nomura H, Fujimoto N, Seiki M, et al. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer. 1996;69:9–16.CrossRefPubMed
24.
Murray GI, Duncan ME, Arbuckle E, et al. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut. 1998;43:791–797.PubMedCrossRef
25.
McDonnell S, Navre M, Coffey RJ, et al. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4:527–533.CrossRefPubMed
26.
Gooz M, Shaker M, Gooz P, et al. Interleukin 1beta induces gastric epithelial cell matrix metalloproteinase secretion and activation during Helicobacter pylori infection. Gut. 2003;52:1250–1256.CrossRefPubMed
27.
Gooz M, Gooz P, Epithelial SmolkaAJ. Epithelial and bacterial metalloproteinases and their inhibitors in H. pylori infection of human gastric cells. Am J Physiol Gastrointest Liver Physiol. 2001;281:G823–G832.PubMed
28.
Kundu P, Mukhopadhyay AK, Patra R, et al. Cag pathogenicity island-independent up-regulation of matrix metalloproteinases-9 and -2 secretion and expression in mice by Helicobacter pylori infection. J Biol Chem. 2006;281:34651–34662.CrossRefPubMed
29.
Caruso R, Fina D, Peluso I, et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol. 2007;178:5957–5965.PubMed
30.
Dixon MF, Genta RM, Yardley JH. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–1181.CrossRefPubMed
31.
Sheu BS, Sheu SM, Yang HB, et al. Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infection. Gut. 2003;52:927–932.CrossRefPubMed
32.
Sheu BS, Odenbreit S, Hung KH, et al. Interaction between host gastric Sialyl-Lewis X and H. pylori SabA enhances H. pylori density in patients lacking gastric Lewis B antigen. Am J Gastroenterol. 2006;101:36–44.CrossRefPubMed
33.
Greene FL. The American joint committee on cancer: Updating the strategies in cancer staging. Bull Am Coll Surg. 2002;87:13–15.PubMed
34.
Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
35.
Chang YW, Oh HC, Jang JY, et al. IL-1beta and IL-8, matrix metalloproteinase 3, and pepsinogen secretion before and after H. pylori eradication in gastroduodenal phenotypes. Scand J Gastroenterol. 2008;43:1184–1193.CrossRefPubMed
36.
Bergin PJ, Anders E, Sicheng W, et al. Increased production of matrix metalloproteinases in Helicobacter pylori-associated human gastritis. Helicobacter. 2004;9:201–210.CrossRefPubMed
37.
Endo K, Maehara Y, Baba H, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res. 1997;17:2253–2258.PubMed
38.
Torii A, Kodera Y, Uesaka K, et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg. 1997;84:133–136.CrossRefPubMed
39.
Honda M, Mori M, Ueo H, et al. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut. 1996;39:444–448.CrossRefPubMed
40.
Kubben FJ, Sier CF, van Duijn W, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer. 2006;94:1035–1040.CrossRefPubMed
41.
Liu XP, Kawauchi S, Oga A, et al. Prognostic significance of matrix metalloproteinase-7 (MMP-7) expression at the invasive front in gastric carcinoma. Jpn J Cancer Res. 2002;93:291–295.PubMed
42.
Kundu P, Mukhopadhyay AK, Patra R, et al. Cag pathogenicity island-independent up-regulation of matrix metalloproteinases-9 and -2 secretion and expression in mice by Helicobacter pylori infection. J Biol Chem. 2006;281:34651–34662.CrossRefPubMed
Metadata
Title
Elevated Serum Matrix Metalloproteinase-3 and -7 in H. pylori-Related Gastric Cancer Can Be Biomarkers Correlating with a Poor Survival
Authors
Yi-Chun Yeh
Bor-Shyang Sheu
Hsiu-Chi Cheng
Yen-Lin Wang
Hsiao-Bai Yang
Jiunn-Jong Wu
Publication date
01-06-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0926-x

Other articles of this Issue 6/2010

Digestive Diseases and Sciences 6/2010 Go to the issue

Erratum

Erratum to: Effects of Combined Pulse Electromagnetic Field Stimulation Plus Glutamine on the Healing of Colonic Anastomosis in Rats

Original Article

Late Relapse of Type 1 Autoimmune Hepatitis After Corticosteroid Withdrawal

Editorial

Probing the Occult: Testing for Blood in the Stools

Original Article

Heartburn and Regurgitation in Pregnancy: The Effect of Fat Ingestion

Original Article

Fecal Occult Blood Test in Patients on Low-Dose Aspirin, Warfarin, Clopidogrel, or Non-steroidal Anti-inflammatory Drugs

Original Article

Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits